Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

Emergent BioSolutions (NYSE: EBS) received a delivery order valued at up to $21.5 million from the U.S. Department of War to supply BioThrax (Anthrax Vaccine Adsorbed) in 2026.

Rhea-AI Summary

Emergent BioSolutions (NYSE: EBS) received a delivery order valued at up to $21.5 million from the U.S. Department of War to supply BioThrax (Anthrax Vaccine Adsorbed) in 2026. The order is placed under Emergent’s existing IDIQ contract W911SR24D0001, led by the Capability Program Executive CBRND in collaboration with the Defense Health Agency. Deliveries will occur in 2026 and the order includes a one-year base period plus two option periods covering 2027 and 2028. The company said the award continues its partnership to provide anthrax vaccination for military personnel at elevated risk.

Positive

• Delivery order worth up to $21.5M for 2026
• Award placed under existing IDIQ contract W911SR24D0001
• Includes a one-year base plus two option years (2027–2028)
• Collaboration with CPE CBRND and Defense Health Agency

Negative

• None.

Argus Jan 9 session

-2.99% close to close Open Argus

Details

News Market Reaction – EBS

On Jan 9, the first trading day after this news, EBS closed 2.99% below the previous close.

Data tracked by StockTitan Argus for the Jan 9 session.

Market Context

This announcement details a BioThrax delivery order worth up to $21.5 million for 2026 from the U.S....

Analysis

This announcement details a BioThrax delivery order worth up to $21.5 million for 2026 from the U.S. Department of War under an existing IDIQ contract, with a one‑year base period and options for 2027–2028. It reinforces Emergent’s biodefense role alongside prior FDA approvals and medical countermeasure contracts. Investors may watch how this order contributes to future revenue mix, follow-on government demand for anthrax countermeasures, and any additional contract modifications or options being exercised.

Key Figures

BioThrax delivery order: $21.5 million Price move: 5.7% 52-week range: $4.02–$14.06 +5 more

BioThrax delivery order

$21.5 million

2026 supply order from U.S. Department of War under existing IDIQ contract

Price move

5.7%

EBS share price change over the last 24 hours prior to this news

52-week range

$4.02–$14.06

EBS 52-week low and high before this announcement

Market cap

$730,027,500

Equity value before the BioThrax order news

Base period

1 year

Initial base period for the 2026 BioThrax delivery order

Option periods

2 years (2027–2028)

Two additional option periods included in the order

Shares outstanding

52,519,964 shares

Common shares outstanding cited in recent Rule 144 filings

Planned insider sale

104,695 shares

Proposed sale under Rule 144 with value $1,336,462.98

Historical Context

5 past events · Latest: Dec 12

5 events

1. Dec 12

   FDA manufacturing approval

   24h Move

   -2.6%

   FDA cleared Winnipeg site for raxibacumab drug product manufacturing and testing.

2. Nov 18

   Product milestone

   24h Move

   +0.2%

   Marked 10-year NARCAN approval anniversary and reiterated naloxone access commitment.

3. Nov 12

   Board change

   24h Move

   -4.5%

   Announced retirement of long-serving director Louis W. Sullivan from the board.

4. Oct 29

   Earnings results

   24h Move

   -0.7%

   Q3 2025 revenue beat guidance and profitability improved, with raised full-year outlook.

5. Oct 28

   Survey on threats

   24h Move

   -2.3%

   Released survey showing heightened concern about biological threats and biodefense support.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

indefinite-delivery/indefinite-quantity, idiq, anthrax vaccine adsorbed

3 terms

indefinite-delivery/indefinite-quantity financial

"This order is under Emergent’s existing indefinite-delivery/indefinite-quantity (IDIQ) contract..."

An indefinite-delivery/indefinite-quantity (IDIQ) contract is a purchasing agreement used mainly by governments where the buyer commits to buy goods or services over a set time but does not specify exact quantities or delivery dates up front. For investors this matters because an IDIQ can create a steady pipeline of potential orders and recurring revenue like a standing grocery list a store can draw from, while leaving total future sales and timing uncertain.

idiq financial

"This order is under Emergent’s existing indefinite-delivery/indefinite-quantity (IDIQ) contract..."

An IDIQ (Indefinite Delivery/Indefinite Quantity) is a type of government procurement contract that sets terms and maximum limits for buying goods or services over a period without specifying exact delivery dates or quantities up front. For investors, an IDIQ signals a potential steady revenue stream and easier repeat business because it gives a company preferred access to future orders under agreed terms—think of it as a standing shopping account that can generate unpredictable but recurring sales.

anthrax vaccine adsorbed medical

"to supply BioThrax® (Anthrax Vaccine Adsorbed) in 2026."

A vaccine that protects against infection by the bacterium that causes anthrax; “adsorbed” means the active ingredient is attached to a harmless mineral to strengthen and prolong the body’s immune response, like adding a slow-release coating to a medicine. Investors watch it because demand, regulatory approvals, stockpiled government purchases, and safety data can drive sales and contracts in the biodefense and vaccine markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GAITHERSBURG, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced it has received a delivery order valued at up to $21.5 million from the U.S. Department of War to supply BioThrax^® (Anthrax Vaccine Adsorbed) in 2026. This order is under Emergent’s existing indefinite-delivery/indefinite-quantity (IDIQ) contract (W911SR24D0001), led by the Capability Program Executive Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND), previously the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency.

“As part of our mission to protect and save lives, we’re proud to help protect those who protect us, including our nation’s service members,” said Paul Williams, senior vice president, head of products business, global government and public affairs at Emergent. “We’re pleased to continue our partnership with the U.S. Department of War to supply BioThrax^® to prepare military personnel at high risk of anthrax exposure.”

Deliveries under this order will take place in 2026. This order includes a one-year base period, with two additional option periods for 2027 and 2028.

About BioThrax^® (Anthrax Vaccine Adsorbed) 
BioThrax^® vaccine is indicated for the active immunization for the prevention of disease caused by Bacillus anthracis in persons 18 through 65 years of age. BioThrax^® is approved for (1) pre-exposure prophylaxis of disease in persons at high risk of exposure; and (2) post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs. The efficacy of BioThrax^® for post-exposure prophylaxis is based solely on studies in animal models of inhalational anthrax. 

Select Important Safety Information 

Contraindication: Severe allergic reaction (e.g., anaphylaxis) after a previous dose of BioThrax^® or a component of the vaccine. Warnings and Precautions: Latex: The stopper of the vial contains natural rubber latex and may cause allergic reactions in latex sensitive individuals. Pregnancy: Avoid use in pregnancy unless the potential benefit outweighs the potential risk to the fetus. Adverse Reactions: The most common (>10%) local (injection-site) adverse reactions observed in clinical studies were tenderness, pain, erythema, edema, and arm motion limitation. The most common (≥5%) systemic adverse reactions were muscle aches, fatigue, and headache. 

Please see the full Prescribing Information for BioThrax^® for additional safety information. 

Disclaimer: The views and opinions expressed herein regarding any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise do not necessarily constitute or imply endorsement, recommendation, or favoring by the United States government and shall not be used for advertising or product endorsement purposes. 

About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. 

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Emergent BioSolutions (EBS) announce on January 8, 2026?

Emergent announced a delivery order of up to $21.5 million from the U.S. Department of War to supply BioThrax in 2026.

Under which contract was the $21.5M BioThrax order placed for EBS?

The order was placed under Emergent’s existing IDIQ contract W911SR24D0001.

When will deliveries for the BioThrax order for EBS occur?

Deliveries are scheduled to take place in 2026 with a one-year base and two option periods for 2027 and 2028.

Which U.S. agencies are involved in the Emergent BioThrax order (EBS)?

The award is led by the Capability Program Executive CBRND in collaboration with the Defense Health Agency.

How large is the 2026 BioThrax delivery order received by EBS?

The delivery order is valued at up to $21.5 million for 2026.

Does the BioThrax order for EBS include options beyond 2026?

Yes; the order includes a one-year base period and two additional option periods covering 2027 and 2028.